FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996282351> ?p ?o ?g. }

• W1996282351 endingPage "2345" @default.
• W1996282351 startingPage "2337" @default.
• W1996282351 abstract "BACKGROUND. Epidermal growth factor receptor (EGFR, HER-1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme-linked immunoadsorbent assay in a Phase III first-line trial of letrozole and tamoxifen and were correlated with patient outcomes. RESULTS. Serum EGFR levels in a control group of 117 healthy, postmenopausal women measured 64.1 ± 13.3 ng/mL (mean ± standard deviation). Using a cutoff EGFR level of 44.1 ng/mL from the control group (5% nonparametric method), 53 of 535 patients (10%) had decreased serum levels of EGFR. Patients with decreased serum EGFR had no significant difference in objective response rate (ORR), clinical benefit rate (CBR), time to progression (TTP), or time to treatment failure (TTF); however, they did have significantly reduced survival compared with patients who had normal serum EGFR levels (median survival, 23.3 months vs. 30.9 months; P = .007). A combined analysis of pretreatment serum EGFR and HER-2 yielded no additional predictive information for ORR, CBR, TTP, or TTF compared to serum HER-2 alone. However, in the current analysis, a subgroup of patients who had decreased serum EGFR and normal serum HER-2 was identified (n = 39 of 535 patients; 7.3%) that had significantly reduced survival compared with patients who had normal serum levels of both EGFR and HER-2 (median survival, 23.5 months vs. 37.1 months; P = .005). In multivariate analysis, a decreased serum EGFR level remained a significant independent prognostic factor for decreased survival (hazards ratio, 1.58; P = .007). CONCLUSIONS. In patients who had metastatic breast cancer, decreased serum EGFR/normal serum HER-2 predicted shorter survival compared with patients who had normal levels of serum EGFR/HER-2. This patient subgroup deserves further study to assess their response to and selection for anti-EGFR-directed therapies. Cancer 2006. © 2006 American Cancer Society." @default.
• W1996282351 created "2016-06-24" @default.
• W1996282351 creator A5006429014 @default.
• W1996282351 creator A5024133393 @default.
• W1996282351 creator A5031275594 @default.
• W1996282351 creator A5033143694 @default.
• W1996282351 creator A5044542632 @default.
• W1996282351 creator A5047198395 @default.
• W1996282351 creator A5051230211 @default.
• W1996282351 creator A5066406142 @default.
• W1996282351 creator A5073379936 @default.
• W1996282351 creator A5088902488 @default.
• W1996282351 date "2006-01-01" @default.
• W1996282351 modified "2023-09-27" @default.
• W1996282351 title "Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer" @default.
• W1996282351 cites W1548966243 @default.
• W1996282351 cites W1596261235 @default.
• W1996282351 cites W1918073772 @default.
• W1996282351 cites W1976090068 @default.
• W1996282351 cites W1977221327 @default.
• W1996282351 cites W1977257587 @default.
• W1996282351 cites W1986335023 @default.
• W1996282351 cites W1992916424 @default.
• W1996282351 cites W1995337883 @default.
• W1996282351 cites W2005204942 @default.
• W1996282351 cites W2012516257 @default.
• W1996282351 cites W2028722335 @default.
• W1996282351 cites W2032359283 @default.
• W1996282351 cites W2053793143 @default.
• W1996282351 cites W2058005725 @default.
• W1996282351 cites W2062051005 @default.
• W1996282351 cites W2062057316 @default.
• W1996282351 cites W2062468721 @default.
• W1996282351 cites W2062839819 @default.
• W1996282351 cites W2064047613 @default.
• W1996282351 cites W2070750298 @default.
• W1996282351 cites W2083364468 @default.
• W1996282351 cites W2085880972 @default.
• W1996282351 cites W2092229345 @default.
• W1996282351 cites W2107686167 @default.
• W1996282351 cites W2108502873 @default.
• W1996282351 cites W2114646523 @default.
• W1996282351 cites W2134850272 @default.
• W1996282351 cites W2135278339 @default.
• W1996282351 cites W2141448895 @default.
• W1996282351 cites W2154692501 @default.
• W1996282351 cites W2158077354 @default.
• W1996282351 cites W2163376196 @default.
• W1996282351 cites W4296024391 @default.
• W1996282351 doi "https://doi.org/10.1002/cncr.22255" @default.
• W1996282351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17048231" @default.
• W1996282351 hasPublicationYear "2006" @default.
• W1996282351 type Work @default.
• W1996282351 sameAs 1996282351 @default.
• W1996282351 citedByCount "34" @default.
• W1996282351 countsByYear W19962823512012 @default.
• W1996282351 countsByYear W19962823512013 @default.
• W1996282351 countsByYear W19962823512015 @default.
• W1996282351 countsByYear W19962823512017 @default.
• W1996282351 countsByYear W19962823512018 @default.
• W1996282351 countsByYear W19962823512019 @default.
• W1996282351 countsByYear W19962823512020 @default.
• W1996282351 countsByYear W19962823512021 @default.
• W1996282351 countsByYear W19962823512022 @default.
• W1996282351 crossrefType "journal-article" @default.
• W1996282351 hasAuthorship W1996282351A5006429014 @default.
• W1996282351 hasAuthorship W1996282351A5024133393 @default.
• W1996282351 hasAuthorship W1996282351A5031275594 @default.
• W1996282351 hasAuthorship W1996282351A5033143694 @default.
• W1996282351 hasAuthorship W1996282351A5044542632 @default.
• W1996282351 hasAuthorship W1996282351A5047198395 @default.
• W1996282351 hasAuthorship W1996282351A5051230211 @default.
• W1996282351 hasAuthorship W1996282351A5066406142 @default.
• W1996282351 hasAuthorship W1996282351A5073379936 @default.
• W1996282351 hasAuthorship W1996282351A5088902488 @default.
• W1996282351 hasBestOaLocation W19962823511 @default.
• W1996282351 hasConcept C121608353 @default.
• W1996282351 hasConcept C126322002 @default.
• W1996282351 hasConcept C143998085 @default.
• W1996282351 hasConcept C170493617 @default.
• W1996282351 hasConcept C2775930923 @default.
• W1996282351 hasConcept C2776362946 @default.
• W1996282351 hasConcept C2777176818 @default.
• W1996282351 hasConcept C2778812593 @default.
• W1996282351 hasConcept C2779438470 @default.
• W1996282351 hasConcept C38180746 @default.
• W1996282351 hasConcept C530470458 @default.
• W1996282351 hasConcept C71924100 @default.
• W1996282351 hasConcept C90924648 @default.
• W1996282351 hasConceptScore W1996282351C121608353 @default.
• W1996282351 hasConceptScore W1996282351C126322002 @default.
• W1996282351 hasConceptScore W1996282351C143998085 @default.
• W1996282351 hasConceptScore W1996282351C170493617 @default.
• W1996282351 hasConceptScore W1996282351C2775930923 @default.
• W1996282351 hasConceptScore W1996282351C2776362946 @default.
• W1996282351 hasConceptScore W1996282351C2777176818 @default.
• W1996282351 hasConceptScore W1996282351C2778812593 @default.
• W1996282351 hasConceptScore W1996282351C2779438470 @default.

• next